Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF149 vs mometasone furoate in Japanese patients with asthma
jRCT2080223504Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atectura breezhaler in asthma (2 arms), sponsored by Novartis. Primary endpoint: Primary efficacy and safety endpoints (unspecified). Started Apr 2017; status: completed.
02
Drugs
atectura breezhaler
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223504.